Skip to content

Evaluation of Combinational Use of Negative Pressure Wound Therapy (NPWT) for Diabetic Foot Wounds

Prospective, Multi-Center Randomized Controlled Trial for the Combinational Use of Negative Pressure Wound Therapy (NPWT) for the Treatment of Diabetic Wounds

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06832787
Enrollment
75
Registered
2025-02-18
Start date
2025-07-22
Completion date
2026-06-30
Last updated
2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer

Keywords

Diabetic Foot Ulcer, Negative Pressure Wound Therapy, Dermal Substitute, Delayed wound closure

Brief summary

Singapore has one of the world's highest diabetes-related lower limb amputation rates in the world. Between 2008 - 2017, 4724/5306 (89.0%) of all major amputations and 6656/7227 (92.1%) of all toe/ray amputations performed in Singapore were for diabetic patients. Diabetic foot ulcers are generally slow to heal and poor wound management may lead to infection and subsequently major amputations. Hence, adequate wound care to achieve wound healing efficiently and effectively is of utmost importance. In the investigators' clinical practice, Negative Pressure Wound Therapy has been the dressing of choice to aid wound closure and prevent infective complications. Drainage of wound exudates helps to reduce and prevent infection, promote granulation tissue proliferation and induce cell growth. When used in combination with dermal substitutes, graft uptake is improved by further promoting proliferation and encouraging tissue regeneration. Wounds can also be closed surgically though primary closure, where the skin is closed and serves as a physical barrier against infection. The technique is not without its pros and cons. Primary closure may decrease healing time and reduce need for additional surgery, but these patients are also at risk of recurrent infection and may require more proximal amputation. These may be circumvented with delayed primary closure, which is the surgical closure of the amputation wound at a delayed timing after amputation. This gives the clinical team time to optimize the wound and ensure that there is no underlying infection prior to closure. The experience of NPWT + Kerecis Omega 3 and delayed primary closure have been positive. To the investigators' current knowledge, there is only one case series reported for the use of fish skin graft in combination with NPWT for the treatment of acute pediatric wounds and two case series for the use of NPWT in diabetic foot wound that has undergone surgical closure. The proposed study would be the first RCT to evaluate effects of combination therapy in both open and closed diabetic foot ulcers.

Interventions

DEVICENegative Pressure Wound Therapy

NPWT applied over wound without any adjuncts

DEVICEKerecis

Kerecis Omega3 Wound Dressing is derived from fish skin and is used as a dermal substitute.

DEVICEDelayed primary closure with local flap

Delayed primary closure with local flap to close wound

Sponsors

Singapore General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age 21-100 * First or last toe ray amputation * Adequate perfusion (either \>50% stenosis on duplex ultrasound or undergone successful revascularization with \<30% residual stenosis)

Exclusion criteria

* Amputations not at first or last toe * Venous ulcers * Heel ulcers * Osteomyelitis * Active Infection * Patients on imunosuppressant * Patients with known allergy to fish * Patients unable to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Number of 100% Wound Closure at 12 weeks12 weeks post-intervention100% Wound Closure defined as re-epithelization without any need for dressing

Secondary

MeasureTime frameDescription
Change in Wong-Baker FACES® Pain Rating Scale Score from Baseline to 12 weeksFrom time of intervention to 12 weeks post-interventionPain score is measured using the Wong-Baker FACES® Pain Rating Scale. Participants will be asked at baseline, and at 4, 8 and 12 weeks subsequently. 0 corresponds to no pain, and 10 corresponds to worst pain imaginable.
Occurrence of infection during study periodUp to 12 weeks post-interventionOccurrence of any infection at index wound during follow-up period is recorded
Time in days taken to achieve complete wound closureUp to 12 weeks post-interventionTime (in days) taken from intervention to 100% wound closure
Occurrence of major amputation during study periodUp to 12 weeks post-interventionOccurrence of major amputation at index limb during follow-up period is recorded
Occurrence of death during study periodUp to 12 weeks post-interventionOccurrence of death during follow-up period is recorded
Occurrence of further minor amputation during study periodUp to 12 weeks post-interventionOccurrence of further minor amputation at index wound during follow-up period is recorded

Countries

Singapore

Contacts

Primary ContactCharyl Yap, B.Sc
charyl.yap.j.q@sgh.com.sg+65 6576 7986

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026